Literature DB >> 23801935

Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.

F S Govani1, A Giess, I G Mollet, M E Begbie, M D Jones, L Game, C L Shovlin.   

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is a disease characterised by abnormal vascular structures, and most commonly caused by mutations in ENG, ACVRL1 or SMAD4 encoding endothelial cell-expressed proteins involved in TGF-β superfamily signalling. The majority of mutations reported on the HHT mutation database are predicted to lead to stop codons, either due to frameshifts or direct nonsense substitutions. The proportion is higher for ENG (67%) and SMAD4 (65%) than for ACVRL1 (42%), p < 0.0001. Here, by focussing on ENG, we report why conventional views of these mutations may need to be revised. Of the 111 stop codon-generating ENG mutations, on ExPASy translation, all except one were premature termination codons (PTCs), sited at least 50-55 bp upstream of the final exon-exon boundary of the main endoglin isoform, L-endoglin. This strongly suggests that the mutated RNA species will undergo nonsense-mediated decay. We provide new in vitro expression data to support dominant negative activity of stable truncated endoglin proteins but suggest these will not generate HHT: the single natural stop codon mutation in L-endoglin (sited within 50-55 nucleotides of the final exon-exon boundary) is unlikely to generate functional protein since it replaces the entire transmembrane domain, as would 8 further natural stop codon mutations, if the minor S-endoglin isoform were implicated in HHT pathogenesis. Finally, next-generation RNA sequencing data of 7 different RNA libraries from primary human endothelial cells demonstrate that multiple intronic regions of ENG are transcribed. The potential consequences of heterozygous deletions or duplications of such regions are discussed. These data support the haploinsufficiency model for HHT pathogenesis, explain why final exon mutations have not been detected to date in HHT, emphasise the potential need for functional examination of non-PTC-generating mutations, and lead to proposals for an alternate stratification system of mutational types for HHT genotype-phenotype correlations.

Entities:  

Keywords:  Alternative splicing; Nonsense-mediated decay; Pervasive transcription; Premature termination codons

Year:  2013        PMID: 23801935      PMCID: PMC3666459          DOI: 10.1159/000350208

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  68 in total

1.  Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function.

Authors:  M E Paquet; N Pece-Barbara; S Vera; U Cymerman; A Karabegovic; C Shovlin; M Letarte
Journal:  Hum Mol Genet       Date:  2001-06-15       Impact factor: 6.150

2.  Soluble endoglin contributes to the pathogenesis of preeclampsia.

Authors:  Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi
Journal:  Nat Med       Date:  2006-06-04       Impact factor: 53.440

3.  Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.

Authors:  Aaron D Bossler; Jennifer Richards; Cicily George; Lynn Godmilow; Arupa Ganguly
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

Review 4.  Nonsense-mediated mRNA decay in mammals.

Authors:  Lynne E Maquat
Journal:  J Cell Sci       Date:  2005-05-01       Impact factor: 5.285

5.  The human intronless melanocortin 4-receptor gene is NMD insensitive.

Authors:  Katja S Brocke; Gabriele Neu-Yilik; Niels H Gehring; Matthias W Hentze; Andreas E Kulozik
Journal:  Hum Mol Genet       Date:  2002-02-01       Impact factor: 6.150

6.  Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1.

Authors:  N Pece-Barbara; U Cymerman; S Vera; D A Marchuk; M Letarte
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

7.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.

Authors:  Laurent David; Christine Mallet; Sabine Mazerbourg; Jean-Jacques Feige; Sabine Bailly
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

8.  A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7.

Authors:  Pinar Bayrak-Toydemir; Jamie McDonald; Nurten Akarsu; Reha M Toydemir; Fernanda Calderon; Timur Tuncali; Wei Tang; Franklin Miller; Rong Mao
Journal:  Am J Med Genet A       Date:  2006-10-15       Impact factor: 2.802

Review 9.  Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways.

Authors:  Marie-Jose Goumans; Franck Lebrin; Gudrun Valdimarsdottir
Journal:  Trends Cardiovasc Med       Date:  2003-10       Impact factor: 6.677

10.  Transcriptional robustness complements nonsense-mediated decay in humans.

Authors:  Claus O Wilke
Journal:  PLoS Genet       Date:  2011-10-13       Impact factor: 5.917

View more
  3 in total

1.  Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.

Authors:  Claire L Shovlin; Ilenia Simeoni; Kate Downes; Zoe C Frazer; Karyn Megy; Maria E Bernabeu-Herrero; Abigail Shurr; Jennifer Brimley; Dilipkumar Patel; Loren Kell; Jonathan Stephens; Isobel G Turbin; Micheala A Aldred; Christopher J Penkett; Willem H Ouwehand; Luca Jovine; Ernest Turro
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

2.  Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.

Authors:  Anna E Hosman; Hannah L Devlin; B Maneesha Silva; Claire L Shovlin
Journal:  Orphanet J Rare Dis       Date:  2013-12-20       Impact factor: 4.123

3.  Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes.

Authors:  Inês G Mollet; Dilipkumar Patel; Fatima S Govani; Adam Giess; Koralia Paschalaki; Manikandan Periyasamy; Elaine C Lidington; Justin C Mason; Michael D Jones; Laurence Game; Simak Ali; Claire L Shovlin
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.